Role of thyroid hormone receptor mutants in hepatocellular carcinoma

甲状腺激素受体突变体在肝细胞癌中的作用

基本信息

  • 批准号:
    7175777
  • 负责人:
  • 金额:
    $ 14.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-12-11 至 2008-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hepatocellular cancer (HCC) is among the most common and most lethal adult cancers worldwide, and is increasing in prevalence in the United States. Over 70% of human hepatocarcinomas express mutant thyroid hormone receptors (TRs). Wild-type TRs function as hormone-regulated transcription factors. We propose to determine the role of the TR mutations associated with hepatocarcinoma in the establishment or progression of these neoplasia. From characterizations in vitro, we know that virtually all of the HCC mutant TRs tested function as dominant-negative inhibitors of wild-type TR function, and that wild-type TRs exert growth suppressive effects in cultured cells that are abrogated by at least certain of the mutant TRs found in HCCs. We now seek to directly examine the role of these HCC TR mutants in oncogenesis in vivo in a transgenic model. Specific aim 1: We will create transgenic mouse lines expressing either wild-type TRalphal or a TRalphal mutant first isolated from a human HCC. Several independent founders will be obtained for each transgenic allele and analyzed. Transgenic mouse lines displaying comparable levels of expression of wild-type and HCC mutant TRs, together with unmodified control mice, will be employed for specific aim 2. Specific aim 2: We will analyze the unmodified and transgene lines for incidence, progression, and type of neoplasia. We are particularly interested in determining if the transgenic strains display altered rates, progression, or presentation of HCC compared to unmodified mice. We will use both a spontaneous and a chemically-induced HCC protocol to investigate the effects of the transgene as an initiator and as a modifier of the neoplastic program. Specific aim 3: We will expand our transgenic study to additional TR mutants associated with HCC, and compare their actions to those of TR mutants associated with other neoplastic or endocrine disorders. Relevance: Alterations in thyroid hormone receptors occur at high frequency in human liver tumors. Our proposed experiments seek to improve our understanding of the basis behind this phenomenon, and may suggest improvements in the treatment of these human cancers.
描述(由申请人提供):肝细胞癌(HCC)是全球最常见和最致命的成人癌症之一,在美国的患病率正在增加。超过70%的人肝癌表达突变型甲状腺激素受体(TRs)。野生型TR作为转录因子调节的转录因子起作用。我们建议确定与肝癌相关的TR突变在这些瘤形成的建立或进展中的作用。从体外表征,我们知道,几乎所有的HCC突变TR测试的功能作为显性负抑制剂的野生型TR功能,和野生型TR发挥生长抑制作用,在培养的细胞中,被废除的至少某些突变TR在HCC中发现。我们现在试图在转基因模型中直接研究这些HCC TR突变体在体内肿瘤发生中的作用。具体目标1:我们将创建表达野生型TRP1或首先从人HCC分离的TRP1突变体的转基因小鼠系。对于每个转基因等位基因,将获得几个独立的建立者并进行分析。显示野生型和HCC突变TR的表达水平相当的转基因小鼠系以及未修饰的对照小鼠将用于特定目的2。具体目标2:我们将分析未修饰和转基因品系的肿瘤发生率、进展和类型。我们特别感兴趣的是,与未修饰的小鼠相比,转基因株是否显示出改变的HCC发生率、进展或表现。我们将使用自发和化学诱导的HCC方案来研究转基因作为肿瘤程序的引发剂和修饰剂的作用。具体目标3:我们将把我们的转基因研究扩展到与HCC相关的其他TR突变体,并将它们的作用与与其他肿瘤或内分泌疾病相关的TR突变体的作用进行比较。相关性:甲状腺激素受体的改变在人类肝脏肿瘤中发生频率很高。我们提出的实验旨在提高我们对这种现象背后的基础的理解,并可能建议改善这些人类癌症的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martin L. Privalsky其他文献

Martin L. Privalsky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martin L. Privalsky', 18)}}的其他基金

Role of cofactors in nuclear hormone receptor function.
辅因子在核激素受体功能中的作用。
  • 批准号:
    8010061
  • 财政年份:
    2010
  • 资助金额:
    $ 14.78万
  • 项目类别:
Role of thyroid hormone receptor mutants in hepatocellular carcinoma
甲状腺激素受体突变体在肝细胞癌中的作用
  • 批准号:
    7392190
  • 财政年份:
    2006
  • 资助金额:
    $ 14.78万
  • 项目类别:
COFACTORS AND NUCLEAR HORMONE RECEPTOR FUNCTION
辅助因子和核激素受体功能
  • 批准号:
    6342516
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:
NEW ASPECTS OF DNA RECOGNITION BY NUCLEAR RECEPTORS
核受体 DNA 识别的新方面
  • 批准号:
    2623459
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:
NEW ASPECTS OF DNA RECOGNITION BY NUCLEAR RECEPTORS
核受体 DNA 识别的新方面
  • 批准号:
    2906236
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:
Role of cofactors in nuclear hormone receptor function.
辅因子在核激素受体功能中的作用。
  • 批准号:
    6896110
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:
Role of cofactors in nuclear hormone receptor function.
辅因子在核激素受体功能中的作用。
  • 批准号:
    6654317
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:
Role of cofactors in nuclear hormone receptor function.
辅因子在核激素受体功能中的作用。
  • 批准号:
    6545145
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:
Role of cofactors in nuclear hormone receptor function.
辅因子在核激素受体功能中的作用。
  • 批准号:
    7316535
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:
Role of cofactors in nuclear hormone receptor function.
辅因子在核激素受体功能中的作用。
  • 批准号:
    8510378
  • 财政年份:
    1998
  • 资助金额:
    $ 14.78万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.78万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了